Increased 5-HT2A receptors in the temporal cortex of Parkinsonian patients with visual hallucinations

Movement Disorders

Volumn 25, Issue 10, 2010, Pages 1399-1408

  Huot, Philippe ^a,b   Johnston, Tom H ^a   Darr, Tayyeba ^a   Hazrati, Lili Naz ^c   Visanji, Naomi P ^c   Pires, Donna ^a   Brotchie, Jonathan M ^a   Fox, Susan H ^a,b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

5 HT2A receptors; Autoradiography; Parkinson's disease; Serotonin; Visual hallucinations

Indexed keywords

AMANTADINE; AMITRIPTYLINE; CABERGOLINE; CHLORPROMAZINE; DECARBOXYLASE INHIBITOR; ENTACAPONE; HALOPERIDOL; IMIPRAMINE; KETANSERIN; LEVODOPA; LEVOMEPROMAZINE; METOCLOPRAMIDE; OLANZAPINE; PERGOLIDE; PRAMIPEXOLE; PROCHLORPERAZINE; QUETIAPINE; ROPINIROLE; SELEGILINE; SEROTONIN 2A RECEPTOR; SPIPERONE; THIORIDAZINE; TOLCAPONE; TRITIUM; SEROTONIN ANTAGONIST;

ADULT; AGED; ARTICLE; AUTORADIOGRAPHY; BRAIN REGION; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MALE; MENTAL DISEASE; MOTOR CORTEX; NEUROTRANSMISSION; ORBITAL CORTEX; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSYCHOSIS; STATISTICAL SIGNIFICANCE; SUBSTANTIA NIGRA; TEMPORAL CORTEX; VISUAL HALLUCINATION; ANALYSIS OF VARIANCE; CADAVER; DRUG EFFECT; HALLUCINATION; METABOLISM; METHODOLOGY; MIDDLE AGED; PARKINSONISM; PATHOLOGY; PROTEIN BINDING; TEMPORAL LOBE;

AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; AUTORADIOGRAPHY; FEMALE; HALLUCINATIONS; HUMANS; KETANSERIN; MALE; MIDDLE AGED; PARKINSONIAN DISORDERS; POSTMORTEM CHANGES; PROTEIN BINDING; RECEPTOR, SEROTONIN, 5-HT2A; SEROTONIN ANTAGONISTS; TEMPORAL LOBE; TRITIUM;

EID: 77954961146     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23083     Document Type: Article

References (58)

1. Marsden CD. The mysterious motor function of the basal ganglia: the Robert Wartenberg Lecture. Neurology 1982;32:514-539.
2. Diederich NJ, Goetz CG, Raman R, Pappert EJ, Leurgans S, Piery V. Poor visual discrimination and visual hallucinations in Parkinson's disease. Clin Neuropharmacol 1998;21:289-295.
3. Fenelon G, Mahieux F, Huon R, Ziegler M. Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. Brain 2000;123(Part 4):733-745.
4. Agid Y, Arnulf I, Bejjani P, et al. Parkinson's disease is a neuropsychiatric disorder. Adv Neurol 2003;91:365-370.
5. Diederich NJ, Goetz CG, Stebbins GT. Repeated visual hallucinations in Parkinson's disease as disturbed external/internal perceptions: focused review and a new integrative model. Mov Disord 2005;20:130-140.
6. Williams DR, Lees AJ. Visual hallucinations in the diagnosis of idiopathic Parkinson's disease: a retrospective autopsy study. Lancet Neurol 2005;4:605-610.
7. Goetz CG, Pappert EJ, Blasucci LM, et al. Intravenous levodopa in hallucinating Parkinson's disease patients: high-dose challenge does not precipitate hallucinations. Neurology 1998;50:515-517.
8. Merims D, Shabtai H, Korczyn AD, Peretz C, Weizman N, Giladi N. Antiparkinsonian medication is not a risk factor for the development of hallucinations in Parkinson's disease. J Neural Transm 2004;111:1447-1453.
9. Jacobs BL, Fornal CA. Serotonin and behavior. A general hypothesis. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology the fourth generation of progress. New York: Raven Press; 1995. p461-469.
10. Naughton M, Mulrooney JB, Leonard BE. A review of the role of serotonin receptors in psychiatric disorders. Hum Psychopharmacol 2000;15:397-415.
11. Gresch PJ, Strickland LV, Sanders-Bush E. Lysergic acid diethylamide-induced Fos expression in rat brain: role of serotonin-2A receptors. Neuroscience 2002;114:707-713.
12. The Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. The Parkinson Study Group. N Engl J Med 1999;340:757-763.
13. Meltzer HY. The importance of serotonin-dopamine interactions in the action of clozapine. Br J Psychiatry Suppl 1992;17:22-29.
14. Schotte A, Janssen PF, Gommeren W, et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl) 1996;124:57-73.
15. Grill-Spector K, Sayres R, Ress D. High-resolution imaging reveals highly selective nonface clusters in the fusiform face area. Nat Neurosci 2006;9:1177-1185.
16. Harding AJ, Broe GA, Halliday GM. Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain 2002;125(Part 2):391-403.
17. Middleton FA, Strick PL. The temporal lobe is a target of output from the basal ganglia. Proc Natl Acad Sci USA 1996;93:8683-8687.
18. Bezard E, Brotchie JM, Gross CE. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat Rev Neurosci 2001;2:577-588.
19. Leysen JE, Awouters F, Kennis L, Laduron PM, Vandenberk J, Janssen PA. Receptor binding profile of R 41 468, a novel antagonist at 5-HT2 receptors. Life Sci 1981;28:1015-1022.
20. Vonsattel JP, Aizawa H, Ge P, et al. An improved approach to prepare human brains for research. J Neuropathol Exp Neurol 1995;54:42-56.
21. Hughes AJ, Daniel SE, Lees AJ. Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology 2001;57:1497-1499.
22. 3H]Ketanserin (R 41 468), a selective 3H-ligand for serotonin2 receptor binding sites. Binding properties, brain distribution, and functional role. Mol Pharmacol 1982;21:301-314.
23. 3H]ketanserin labels serotonin 5-HT2 and alpha 1-adrenergic receptors in human brain cortex. J Cardiovasc Pharmacol 1987;10(Suppl 3):S48-S50.
24. Oquendo MA, Russo SA, Underwood MD, et al. Higher postmortem prefrontal 5-HT2A receptor binding correlates with lifetime aggression in suicide. Biol Psychiatry 2006;59:235-243.
25. Darchen F, Scherman D, Laduron PM, Henry JP. Ketanserin binds to the monoamine transporter of chromaffin granules and of synaptic vesicles. Mol Pharmacol 1988;33:672-677.
26. Lyon RA, Davis KH, Titeler M. 3H-DOB (4-bromo-2,5- dimethoxyphenylisopropylamine) labels a guanyl nucleotide-sensitive state of cortical 5-HT2 receptors. Mol Pharmacol 1987;31:194-199.
27. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-442.
28. Pazos A, Probst A, Palacios JM. Serotonin receptors in the human brain. IV. Autoradiographic mapping of serotonin-2 receptors. Neuroscience 1987;21:123-139.
29. Fox SH, Brotchie JM. 5-HT2C receptor binding is increased in the substantia nigra pars reticulata in Parkinson's disease. Mov Disord 2000;15:1064-1069.
30. Weisstaub NV, Zhou M, Lira A, et al. Cortical 5-HT2A receptor signaling modulates anxiety-like behaviors in mice. Science 2006;313:536-540.
31. Paulus W, Jellinger K. The neuropathologic basis of different clinical subgroups of Parkinson's disease. J Neuropathol Exp Neurol 1991;50:743-755.
32. Mayeux R, Stern Y, Cote L, Williams JB. Altered serotonin metabolism in depressed patients with Parkinson's disease. Neurology 1984;34:642-646.
33. Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther 2002;303:791-804.
34. Elliott MS, Ballard CG, Kalaria RN, Perry R, Hortobagyi T, Francis PT. Increased binding to 5-HT1A and 5-HT2A receptors is associated with large vessel infarction and relative preservation of cognition. Brain 2009;132(Part 7):1858-1865.
35. Halliday GM, Blumbergs PC, Cotton RG, Blessing WW, Geffen LB. Loss of brainstem serotonin- and substance P-containing neurons in Parkinson's disease. Brain Res 1990;510:104-107.
36. Hillarp NA, Fuxe K, Dahlstrom A. Demonstration and mapping of central neurons containing dopamine, noradrenaline, and 5-hydroxytryptamine and their reactions to psychopharmaca. Pharmacol Rev 1966;18:727-741.
37. Fahn S, Libsch LR, Cutler RW. Monoamines in the human neostriatum: topographic distribution in normals and in Parkinson's disease and their role in akinesia, rigidity, chorea, and tremor. J Neurol Sci 1971;14:427-455.
38. D'Amato RJ, Zweig RM, Whitehouse PJ, et al. Aminergic systems in Alzheimer's disease and Parkinson's disease. Ann Neurol 1987;22:229-236.
39. Scatton B, Javoy-Agid F, Rouquier L, Dubois B, Agid Y. Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease. Brain Res 1983;275:321-328.
40. Radja F, Descarries L, Dewar KM, Reader TA. Serotonin 5-HT1 and 5-HT2 receptors in adult rat brain after neonatal destruction of nigrostriatal dopamine neurons: a quantitative autoradiographic study. Brain Res 1993;606:273-285.
41. Laprade N, Radja F, Reader TA, Soghomonian JJ. Dopamine receptor agonists regulate levels of the serotonin 5-HT2A receptor and its mRNA in a subpopulation of rat striatal neurons. J Neurosci 1996;16:3727-3736.
42. Woodward RM, Panicker MM, Miledi R. Actions of dopamine and dopaminergic drugs on cloned serotonin receptors expressed in Xenopus oocytes. Proc Natl Acad Sci USA 1992;89:4708-4712.
43. Oz M, Zhang L, Rotondo A, Sun H, Morales M. Direct activation by dopamine of recombinant human 5-HT1A receptors: comparison with human 5-HT2C and 5-HT3 receptors. Synapse 2003;50:303-313.
44. Bhattacharyya S, Raote I, Bhattacharya A, Miledi R, Panicker MM. Activation, internalization, and recycling of the serotonin 2A receptor by dopamine. Proc Natl Acad Sci USA 2006;103:15248-15253.
45. Carta M, Carlsson T, Kirik D, Bjorklund A. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain 2007;130(Part 7):1819-1833.
46. Carta M, Carlsson T, Munoz A, Kirik D, Bjorklund A. Serotonin-dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesias. Prog Brain Res 2008;172:465-478.
47. Fabbrini G, Brotchie JM, Grandas F, Nomoto M, Goetz CG. Levodopa-induced dyskinesias. Mov Disord 2007;22:1379-1389; quiz 1523.
48. Goodale MA, Milner AD. Separate visual pathways for perception and action. Trends Neurosci 1992;15:20-25.
49. Halgren E, Dale AM, Sereno MI, Tootell RB, Marinkovic K, Rosen BR. Location of human face-selective cortex with respect to retinotopic areas. Hum Brain Mapp 1999;7:29-37.
50. Beauchamp MS, Argall BD, Bodurka J, Duyn JH, Martin A. Unraveling multisensory integration: patchy organization within human STS multisensory cortex. Nat Neurosci 2004;7:1190-1192.
51. Beauchamp MS, Lee KE, Argall BD, Martin A. Integration of auditory and visual information about objects in superior temporal sulcus. Neuron 2004;41:809-823.
52. Ibarretxe-Bilbao N, Ramirez-Ruiz B, Tolosa E, et al. Hippocampal head atrophy predominance in Parkinson's disease with hallucinations and with dementia. J Neurol 2008;255:1324-1331.
53. 18F]setoperone PET study. Mov Disord 2008;23(Suppl 1):S75.
54. Parent A, Hazrati LN. Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop. Brain Res Brain Res Rev 1995;20:91-127.
55. Bishop C, Tessmer JL, Ullrich T, Rice KC, Walker PD. Serotonin 5-HT2A receptors underlie increased motor behaviors induced in dopamine-depleted rats by intrastriatal 5-HT2A/2C agonism. J Pharmacol Exp Ther 2004;310:687-694.
56. Dave KD, Fernando GS, Quinn JL, Harvey JA, Aloyo VJ. Serotonin 5-HT2A receptors in the CA1 field of the hippocampus mediate head movements in the rabbit. Psychopharmacology (Berl) 2004;176:287-295.
57. Iravani MM, Jackson MJ, Kuoppamaki M, Smith LA, Jenner P. 3,4-Methylenedioxymethamphetamine (ecstasy) inhibits dyskinesia expression and normalizes motor activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- treated primates. J Neurosci 2003;23:9107-9115.
58. Durif F, Debilly B, Galitzky M, et al. Clozapine improves dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study. Neurology 2004;62:381-388.